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In this study we followed up the side effects of adjuvant radiotherapy in patients with testicular seminoma 
stage I over a period from 13 to 84 months (median 28 months). The most frequent side effects during 
radiotherapy were gastrointestinal (nausea/vomiting), psychological, cognitive, and minor sexual problems. 
The reported side effects were treated by antiemetics and anxiolytics.
After radiotherapy, the side effects persisted in 6 % of patients, but only a few of them required additional 
treatment. Healthy children were born to 76 % of patients in the 18 to 39 years age group. This study shows 
that adjuvant radiotherapy of the para-aortic lymph nodes with the total dosage of 24 Gy in 16 daily 
fractions administered to testicular seminoma patients causes acceptable side effects, does not adversely 
affect quality of life and fertility, if the approach to treatment is individual and family consulting is provided. 
This makes adjuvant radiotherapy of the para-aortic lymph nodes an acceptable treatment for testicular 
seminoma stage I patients.
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Testicular germ cell tumours are relatively rare, 
appearing in 1 % of all tumours in male patients (1). 
Most of these tumours originate in germ cells 
(seminoma and non-seminoma germ cell testicular 
tumours, sometimes the combination of these two 
groups), and more than 70 % of patients are diagnosed 
the disease while it is still in stage I. These malignancies 
represent the most common solid tumours in young 
men aged 25 to 35 years and are highly curable.
Pure seminoma is the most common variant of 
testicular germ cell tumours, accounting for in about 
40 % of all cases. Seminoma is highly radiosensitive 
and chemosensitive (2). Adjuvant radiotherapy of the 
para-aortic lymph nodes after orchidectomy is one of 
the three approaches to management, which include 
surveillance, adjuvant radiotherapy (infradiaphragmatic 
20 Gy to 25 Gy to include the para-aortic nodes), and 
adjuvant chemotherapy with carboplatin with area 
under the curve =7, (AUC=7) x 1 cycle or AUC=7 x 
2 cycles (3-6).
Many surveillance studies suggest that 15 % to 
20 % of these patients develop a metastatic disease. 
The adjuvant therapy is successful in 96 % to 100 % 
of patients (4, 7, 8). Many studies suggest that 
carboplatin is not inferior to adjuvant radiotherapy in 
preventing metastatic relapse. The estimation of the 
therapy success, however, should include the quality 
of life during as well as after therapy. To improve the 
quality of life , it is therefore advisable to know which 
side effects to expect and how to prevent them).
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The aim of this study was to establish the side 
effects during and after radiotherapy in patients with 
testicular seminoma stage I and how to prevention 
and/or treat them.
References provide numerous data on toxicity of 
radiotherapy in the adjuvant treatment of testicular 
seminoma. Most of the clinical studies of long-term 
surveillance are based on larger irradiation fi elds or 
higher daily doses. There are neither suffi cient data 
on the long-term surveillance of patients treated with 
irradiation of the para-aortic fi elds, nor on the adjuvant 
chemotherapy with carboplatin. The usual toxicity 
after radiotherapy and chemotherapy is either the acute 
toxicity during and immediately after therapy, or the 
late or postponed toxicity monitored years after the 
therapy.
Acute toxicity usually involves mild gastrointestinal 
symptoms and the symptoms of myelosuppression, 
but late effects may include radiation-induced 
secondary malignancies, increased risk of peptic 
ulceration, and impaired fertility, and sexual function 
(9-11).
SUBJECTS AND METHODS
The study included 115 patients with testicular 
seminoma stage I, treated with adjuvant radiotherapy 
at the Clinical Hospital Centre Zagreb, Department of 
Oncology. The average patient age at diagnosis was 
34 (19 to 72) years. Their socio-demographic 
characteristics are summarised in Table 1. All patients 
were treated with adjuvant radiotherapy of the para-
aortic lymph nodes with 15 MV linear accelerator 
photons from two opposite anteroposterior fi elds. The 
tumour dose was 24 Gy divided in 16 daily fractions. 
Para-aortic fi eld borders included superior T10/T11 
intervertebral disk, inferior L5/S1 intervertebral disk, 
lateral margins to the vertebral bodies including the 
transverse process bilaterally (Figure 1a,1b,1c), and 
the left renal hilum for the left testicular seminoma. 
The patients wore a gonadal shield. All patients were 
stage IA or IB. Before orchidectomy, all had standard 
laboratory tests, tests for serum tumour markers alpha-
fetoprotein (AFP), lactate dehydrogenase (LDH), and 
beta-human chorionic gonadotropin (bHCG), chest 
X-rays, abdominopelvic CT scans, and the ultrasound 
of the testes.
Before radiotherapy (post-orchidectomy), all 
patients had normal serum tumour markers LDH, 
bHCG, and AFP. Before orchidectomy 18 % had 
abnormal bHCG and 14 % abnormal LDH. Follow-up 
after radiotherapy took place every six months in the 
fi rst fi ve years, then annualy and included standard 
laboratory tests, AFP, LDH, and bHCG tests; chest 
X-rays, abdominopelvic CT scans or MRI, and the 
ultrasound of the testes.
For the follow-up of radiotherapy side effects we 
used the European Organisation for Research and 
Treatment of Cancer (EORTC) QLQ-C30 questionnaire 
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Figure 1a, 1b, 1c Para-aortic fi elds for early-stage seminoma
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(12, 13) and the recommended toxicity criteria of the 
Radiation Therapy Oncology Group (RTOG) (14). In 
the questionnaire the patients evaluated the severity 
of their side effects on a four-point scale: 1) not at all; 
2) a little; 3) quite a bit; 4) very much (12). Their 
physical condition and the quality of life were scored 
on a seven-point scale from “very poor” to 
“excellent”.
A smaller part of the data was taken from standard 
routine medical checkup documentation. Patients 
filled out the questionnaire immediately after 
radiotherapy and again in December of 2010, which 
means that the fi rst and the second questionnaire were 
separated by 13 to 84 months (median 28 months).
RESULTS AND DISCUSSION
The male population with testicular seminoma is 
generally of younger age. Due to successful therapy 
management, long-term survival is excellent. 
Therefore, seminoma patients are an ideal population 
to formulate evidence-based guidelines for reducing 
therapy side effects.
During and after radiotherapy, our patients 
complained of gastrointestinal side effects, fatigue and 
diminished fitness, affected psychological and 
cognitive functions and sexual problems. The sexual 
side effects are given in Figure 2. Other side effects 
listed in Table 2 refer to physical well-being, intestinal 
function, urinary function, pain, psychological well-
being, physical autonomy, relational life, body image, 
job modifi cation, subjective evaluations of global life 
quality, and the role of treatment in life-style changes. 
During radiotherapy four patients required treatment 
of side effects; two with antiemetics (ondansetron 
hydrochloride, 8 mg d-1 to 16 mg d-1) for vomiting 
which occurred in the fi rst three days of radiotherapy 
and two with anxiolytics (oral diazepam 2 mg d-1 to 5 
mg d-1) in the fi rst week of radiotherapy. One patient 
had to withdraw from radiotherapy for three days due 
to thrombocytopenia G1, according to RTOG (14).
After radiotherapy, six patients showed side 
effects; three required no therapy, while three required 
therapy occasionally. Occasional side effects were 
gastritis or stomach pain, which were treated with 
esomeprazol magnesium 20 mg d-1. One patient had 
occasional diarrhoea for up to three months after 
radiotherapy, but required no therapy. A year after 
radiotherapy, one patient had two episodes of acute 
pancreatitis, which required hospitalisation. One to 
six years after radiotherapy, 80 % of the patients aged 
from 18 to 29 years and 67 % of those aged 30 to 39 
years had healthy children.
Two patients had a relapse of seminoma (1.7 %).
The fi rst was irradiated in 2008. He had a left testicular 
seminoma pT2, a lymphatic invasion and extending 
through the tunica albuginea, pT2N0M0S0, stage IB. 
The pathohistological tumour size was 4.5 cm. 
Fourteen months after the para-aortic radiotherapy, 
CT detected the lymph node size 5.5 cm x 5.6 cm 
(outside of the irradiation fi eld) in the left pelvis. He 
was treated with four cycles of BEP chemotherapy 
Figure 2  Infl uence of adjuvant radiotherapy on patients’ sexual life
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and is now healthy. The second patient had a relapse 
of seminoma in the right inguinal lymphnodes four 
months after the para-aortic radiotherapy. Initially, he 
had a right testicular seminoma pT2N0M0S0, stage 
IB. The pathohistological tumour size was 7.3 cm with 
a vascular invasion. He was treated with three cycles 
of BEP chemotherapy and is now healthy.
Seminomas are highly sensitive to chemotherapy 
and radiotherapy. Two management approaches have 
dominated the clinical practice in the past 20 years: 
irradiation and survival follow up. Currently, 
monochemotherapy with carboplatin may be proposed 
as the third approach. The role of adjuvant 
monochemotherapy with carboplatin is less established 
(15-17).
Two Medical Research Council (MRC) studies of 
5 years follow-up (18, 19) reported signifi cantly lower 
toxic effects after the radiotherapy of testicular 
seminoma when the fi eld was reduced from “dogleg” 
to para-aortic and when the dose was reduced from 
30 Gy to 20 Gy, while the therapy outcome was the 
same.
A meta-analysis (20) of surveillance studies 
suggest that risk factors such as the tumour size >4 cm 
and the pathological infi ltration of rete testis result in 
15 % to 20 % of testicular seminoma in patients with 
undetectable disease in the para-aortic region. 
Therefore, follow-up should include patients with no 
risk factors (7, 21). The problem with follow up is the 
number of patients who come to the control examination 
irregularly. Beside the side effects, the quality of life 
is also important parameter included in follow-up.
Opinions are divided on the choice of treatment 
with carboplatin between one and two cycles and the 
respective dosage. However, the relapse is less likely 
with carboplatin in two cycles (AUC 7) (22-25). As 
for chemotherapy and radiotherapy, present data (4) 
suggests that the effects of treating testicular seminoma 
stage I with carboplatin or with irradiation of the para-
aortic lymph nodes are identical. This shifts the focus 
on the side effects as important elements in the correct 
selection of treatment, in which patient’s agreement 
is part of the decision process (26).
Dose reduction and the limiting of the irradiation 
field to the para-aortic area seem to reduce the 
scattered dosage to the remaining testicle, and 
therefore the risk of impaired fertility and genetic 
damage. Additionally, the cumulative dose of 2 Gy in 
multiple fractions was reported to induce azoospermia, 
which may be associated with scattered irradiation of 
the testis from inverted Y fi eld (27, 28).
Chemotherapy of Hodgkin’s disease alone caused 
less severe fertility function disturbances than a 
combination of chemotherapy and pelvic irradiation 
(48 % vs. 89 %) (29).
Advances in radiotherapy and chemotherapy with 
similar results may in near future provide an answer 
as to which therapy option is less toxic (30).
Table 2 Side effects during and after radiotherapy





nausea and vomiting 15
nausea and hard stool 8
nausea and diarrhoea 7
nausea, vomiting and diarrhoea 4
nausea and fatigue 27
no side effects 7
the same weight as before radiotherapy, 
no anorexia
46
anorexia with weight loss ≤ 5 % 28
anorexia with weight loss ≤ 15 % 23




worried and anxious 35
worried, anxious and depressed 32
memory and concentration problems 8





fi nancial problems due to absence from 
work
21
social problems (social life and going 
out)
23
Physical condition in the last week of 
radiotherapy
poor, very poor 23
medium 20
good/excellent 57
Quality of life in the last week of 
radiotherapy
poor, very poor 14
medium 20
good/excellent 66
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Radiotherapy has been the accepted cancer therapy 
option for at least fi ve decades. Our study describes 
side effects in patients with testicular seminoma stage 
I after radiotherapy and is in concordance with similar 
studies (11, 31). According to a large multicentre 
studies, 4 % to 7 % of patients developed the secondary 
cancer after radiotherapy of testicular cancer, of which 
the highest risk was for gastrointestinal cancers (9, 
32). In the past, however, irradiation fi elds were larger 
and so was the total dose of irradiation (33, 34). A 
transparent communication and individual approach 
to patients will produce the best results and better 
treatment of radiotherapy side effects. The important 
problem is the change in sexual activity due to either 
psychological reasons (35, 36) or the awareness of 
fertility issues (11, 28). This study contributes to the 
current knowledge of patient condition after exposure 
to ionising radiation, fertility options, side effects in 
order to identify procedures for resolving patient’s 
problems and improving living conditions as soon 
after radiotherapy as possible.
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Sažetak
NUSPOJAVE ADJUVANTNOG ZRAČENJA BOLESNIKA SA SEMINOMOM TESTISA STADIJA I
U ovoj studiji nuspojave adjuvantne radioterapije kod bolesnika sa seminomom testisa stadija I praćene 
su u periodu od 13 do 84 mjeseca (medijan 28 mjeseci). Tijekom radioterapije bolesnici su imali najčešće 
nuspojave od strane probavnog sustava (mučnina/povraćanje), psihološke i kognitivne probleme i blaže 
seksualne smetnje. Navedene nuspojave uspješno su tretirane antiemeticima i anksioliticima. Nakon 
radioterapije 76 % bolesnika dobne skupine od 18 do 39 godina ima zdravu djecu. Zaključno, ovo 
istraživanje pokazuje da adjuvantno zračenje paraaortalnih limfnih čvorova s ukupnom dozom od 24 Gy 
u 16 frakcija kod bolesnika sa seminomom testisa stadija I uzrokuje prihvatljive nuspojave uz prihvatljivu 
kvalitetu života, fertilitet, koristeći individualni pristup liječenju te obiteljsko savjetovalište. Adjuvantna 
radioterapija seminoma testisa stadija I je prihvatljiv oblik liječenja.
KLJUČNE RIJEČI: kvaliteta života, paraaortalno polje zračenja, praćenje, radioterapijska toksičnost, 
rani stadij seminoma
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